Aurinia Pharmaceuticals Reports Q1 Loss, Tops Revenue Estimates

AUPH Stock  USD 9.20  0.22  2.45%   
Under 70 percent of all Aurinia Pharmaceuticals' traders are curious in acquiring. The analysis of the overall investor sentiment regarding Aurinia Pharmaceuticals suggests that a large number of traders are confidant. Aurinia Pharmaceuticals' investing sentiment shows overall attitude of investors towards Aurinia Pharmaceuticals.
  
Aurinia delivered earnings and revenue surprises of 82.35 percent and 8.65, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock

Read at finance.yahoo.com
Yahoo News
  

Aurinia Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Aurinia Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Aurinia Pharmaceuticals Fundamental Analysis

We analyze Aurinia Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aurinia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aurinia Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Shares Shorted

Number Of Shares Shorted Comparative Analysis

Aurinia Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Aurinia Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aurinia Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Aurinia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aurinia Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Aurinia Pharmaceuticals Related Equities

BTAIBioXcel Therapeutics   6.43   
0%
100.0%
TGTXTG Therapeutics   1.15   
0%
17.0%
MDGLMadrigal Pharmaceuticals   0.30   
4.0%
0%
EXELExelixis   0.65   
10.0%
0%
PTCTPTC Therapeutics   1.33   
20.0%
0%
AXSMAxsome Therapeutics   1.44   
22.0%
0%
SRPTSarepta Therapeutics   1.52   
23.0%
0%
TERNTerns Pharmaceuticals   1.87   
29.0%
0%
AKROAkero Therapeutics   2.22   
34.0%
0%
VKTXViking Therapeutics   2.81   
43.0%
0%
MCRBSeres Therapeutics   3.61   
56.0%
0%
HEPAHepion Pharmaceuticals   4.00   
62.0%
0%

Complementary Tools for Aurinia Stock analysis

When running Aurinia Pharmaceuticals' price analysis, check to measure Aurinia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aurinia Pharmaceuticals is operating at the current time. Most of Aurinia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aurinia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aurinia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aurinia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Money Managers
Screen money managers from public funds and ETFs managed around the world
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators